Search hospitals > California > Marysville
Fremont - Rideout Cancer Center
Claim this profileMarysville, California 95901
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast cancer
Conducts research for Prostate Cancer
118 reported clinical trials
16 medical researchers
Summary
Fremont - Rideout Cancer Center is a medical facility located in Marysville, California. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer, Prostate Cancer and other specialties. Fremont - Rideout Cancer Center is involved with conducting 118 clinical trials across 230 conditions. There are 16 research doctors associated with this hospital, such as Edward J. Kim, Jonathan W. Riess, Mamta Parikh, and Joseph M. Tuscano.Area of expertise
1Lung Cancer
Global LeaderStage II
Stage IV
Stage I
2Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
Top PIs
Edward J. KimUniversity of California Davis Comprehensive Cancer Center2 years of reported clinical research
Studies Pancreatic Cancer
Studies Liver Cancer
33 reported clinical trials
70 drugs studied
Jonathan W. RiessUniversity of California Davis Comprehensive Cancer Center6 years of reported clinical research
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
22 reported clinical trials
33 drugs studied
Mamta ParikhUniversity of California Davis Comprehensive Cancer Center5 years of reported clinical research
Studies Bladder Cancer
Studies Prostate Cancer
21 reported clinical trials
36 drugs studied
Joseph M. TuscanoUniversity of California Davis Comprehensive Cancer Center1 year of reported clinical research
Expert in Lymphoma
Studies Non-Hodgkin's Lymphoma
22 reported clinical trials
45 drugs studied
Clinical Trials running at Fremont - Rideout Cancer Center
Lung Cancer
Breast Cancer
Bladder Cancer
Breast cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Oropharyngeal Carcinoma
Laryngeal Cancer
Head and Neck Squamous Cell Carcinoma
Throat Cancer
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
High-Dose Radiation + Chemotherapy and Immunotherapy
for Non-Small Cell Lung Cancer
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Recruiting2 awards Phase 314 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Fremont - Rideout Cancer Center?
Fremont - Rideout Cancer Center is a medical facility located in Marysville, California. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer, Prostate Cancer and other specialties. Fremont - Rideout Cancer Center is involved with conducting 118 clinical trials across 230 conditions. There are 16 research doctors associated with this hospital, such as Edward J. Kim, Jonathan W. Riess, Mamta Parikh, and Joseph M. Tuscano.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.